156 related articles for article (PubMed ID: 17576061)
21. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
[TBL] [Abstract][Full Text] [Related]
22. Biaryl substituted hydantoin compounds as TACE inhibitors.
Yu W; Tong L; Kim SH; Wong MK; Chen L; Yang DY; Shankar BB; Lavey BJ; Zhou G; Kosinski A; Rizvi R; Li D; Feltz RJ; Piwinski JJ; Rosner KE; Shih NY; Siddiqui MA; Guo Z; Orth P; Shah H; Sun J; Umland S; Lundell DJ; Niu X; Kozlowski JA
Bioorg Med Chem Lett; 2010 Sep; 20(17):5286-9. PubMed ID: 20663669
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
Park K; Aplasca A; Du MT; Sun L; Zhu Y; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2006 Aug; 16(15):3927-31. PubMed ID: 16723229
[TBL] [Abstract][Full Text] [Related]
24. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
Bioorg Med Chem Lett; 2003 Dec; 13(24):4293-7. PubMed ID: 14643312
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.
Letavic MA; Axt MZ; Barberia JT; Carty TJ; Danley DE; Geoghegan KF; Halim NS; Hoth LR; Kamath AV; Laird ER; Lopresti-Morrow LL; McClure KF; Mitchell PG; Natarajan V; Noe MC; Pandit J; Reeves L; Schulte GK; Snow SL; Sweeney FJ; Tan DH; Yu CH
Bioorg Med Chem Lett; 2002 May; 12(10):1387-90. PubMed ID: 11992783
[TBL] [Abstract][Full Text] [Related]
26. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
[TBL] [Abstract][Full Text] [Related]
27. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
[TBL] [Abstract][Full Text] [Related]
29. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
30. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
[TBL] [Abstract][Full Text] [Related]
31. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.
Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Christ DD; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
Bioorg Med Chem Lett; 2003 Dec; 13(24):4299-304. PubMed ID: 14643313
[TBL] [Abstract][Full Text] [Related]
32. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
[TBL] [Abstract][Full Text] [Related]
33. A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.
Chen XT; Ghavimi B; Corbett RL; Xue CB; Liu RQ; Covington MB; Qian M; Vaddi KG; Christ DD; Hartman KD; Ribadeneira MD; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Apr; 17(7):1865-70. PubMed ID: 17276676
[TBL] [Abstract][Full Text] [Related]
34. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
[TBL] [Abstract][Full Text] [Related]
35. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.
Sheppeck JE; Tebben A; Gilmore JL; Yang A; Wasserman ZR; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1408-12. PubMed ID: 17188861
[TBL] [Abstract][Full Text] [Related]
36. Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.
Nuti E; Casalini F; Avramova SI; Santamaria S; Fabbi M; Ferrini S; Marinelli L; La Pietra V; Limongelli V; Novellino E; Cercignani G; Orlandini E; Nencetti S; Rossello A
J Med Chem; 2010 Mar; 53(6):2622-35. PubMed ID: 20180536
[TBL] [Abstract][Full Text] [Related]
37. Current perspective of TACE inhibitors: a review.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 Jan; 17(2):444-59. PubMed ID: 19095454
[TBL] [Abstract][Full Text] [Related]
38. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
[TBL] [Abstract][Full Text] [Related]
39. The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.
Zhao Y; Yu J; Gu J; Huang W
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):181-7. PubMed ID: 21406033
[TBL] [Abstract][Full Text] [Related]
40. Novel TACE inhibitors in drug discovery: a review of patented compounds.
Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
